Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US69329Y1047
Ticker PDLI
Company PDL BIOPHARMA
Currency $
Price
Aware Investor Index (AII) 98.5965
Recommendation STRONG BUY
P/E 2.32
ROE 21.98 %
Capitalization 354,912,180 $
Dividend Yield 27.65 %
P/S 0.60
AII Position 40
P/E Position 2
ROE Position 141
Capitalization Position 777
Dividend Yield Position 2
Sales 590,448,000 $
10-Year Average Earnings 152,946,700 $
Shares Outstanding 163,554,000
Equity 695,952,000 $
Dividend per Share 0.6 $
Industry Biotechnology
Country United States
PDL BIOPHARMA Investor Relations Web Site http://investor.pdl.com







Sales:

YEAR MONTH AMOUNT
2015 12 590,448,000.00 $
2014 12 581,225,000.00 $
2013 12 442,921,000.00 $

Earnings:

YEAR MONTH AMOUNT
2015 12 332,795,000.00 $
2014 12 322,244,000.00 $
2013 12 264,530,000.00 $
2012 12 211,669,000.00 $
2011 12 199,389,000.00 $
2010 12 91,874,000.00 $
2009 12 189,660,000.00 $
2008 12 68,387,000.00 $
2007 12 -21,061,000.00 $
2006 12 -130,020,000.00 $

Equity:

YEAR MONTH AMOUNT
2015 12 695,952,000.00 $
2014 12 460,437,000.00 $
2013 12 113,489,000.00 $
2012 12 -68,122,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2015 12 163,554,000
2014 12 173,110,000
2013 12 159,343,000
2012 12 146,403,000

 












Bloomberg News for PDL BIOPHARMA:

Feb 10, 2012
Nasdaq Short Interest as of Jan. 31
283 64,685 PDII PDI INC 37,088 35,330 10,856 PDLI PDL BIOPHARMA IN 15,552,112 15,369,417 2,425,494 PGC PEAPACK GLADSTON...
Dec 1, 2003
Pacific Growth Ups Protein Design to 'Overweight'
Pacific Growth upgraded Protein Design Labs (PDLI ) to overweight. Protein Design and Genentech agreed in principle...
Sep 6, 2005
First Albany Ups Protein Design Labs
First Albany upgrades Protein Design Labs (PDLI ) to strong buy from buy on Tuesday, citing the company's positive results from a study of ularitide as a potential treatment for heart failure...
Aug 5, 2005
Baidu.com Soars in IPO
of 41 cents to 43 cents on revenue of $269 million to $279 million. Protein Design Labs (PDLI ) posted second quarter earnings per share of 9 cents, vs. a 12-cent loss (pro forma)...
Jul 5, 2005
PowerPicks Heat Up in June
4,339 NR None 5 - Health Care Equipment PDLI Protein Design Labs 1,731 C 400 5 - Biotechnology...
Nov 2, 2001
Computer Sciences Posts Lower Earnings
include charges of $0.17 per share after-tax related to September 11. Protein Design (PDLI ) posted $0.02 3Q loss vs. $0.06 loss on 74% revenue rise. The company expects breakeven...
Feb 1, 2002
Waste Management Shares Take a Spill
II suppliers. JP Morgan upgraded. CIBC World reiterates strong buy on Protein Design (PDLI ), citing the time line for the release of efficacy data for two key pipeline compounds...
Mar 21, 2002
Morgan Stanley Upgrades Protein Design to 'Overweight'
Morgan Stanley upgraded Protein Design (PDLI ) to overweight from underweight. The biotech company doesn't plan additonal development of Zenapax as a therapy for psoriasis, as the...
May 20, 2002
MIM Raises EPS Outlook
therapy for treatment of metastatic breast cancer and other solid tumors. Protein Design (PDLI ) says Phase III results of its Zamyl in patients with relapsed or refractory acute myeloid...
May 10, 2002
US Airways Mulls Bankruptcy
revenue rise, and sees 8%-11% higher Q2 EBITDA on a 7%-10% revenue rise. Protein Design (PDLI ) posted $0.02 vs. $0.07 Q1 EPS on 18% lower revenue. The drug maker sees a $0.17-$0...


Google News for PDL BIOPHARMA:

StreetInsider.com - 3 days ago
PDL BioPharma (PDLI) Settles Keytruda Patent Infringement ...
PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017, the Company entered into a settlement ...
StockNewsJournal
The Charts Expose On PDL BioPharma, Inc. (PDLI) Is Causing A Stir
The technicals for PDL BioPharma, Inc. (PDLI) have taken shape, and with them a comprehensive picture has emerged. This is the current state ...
TopChronicle
Market Focus: Zooming in on Shares of PDL BioPharma, Inc ...
PDL BioPharma, Inc. (NASDAQ:PDLI) presently has an EV or Enterprise Value of 481762. The EV helps show how the market assigns value to ...
StandardOracle
Active Volume Stock: PDL BioPharma, Inc. (PDLI)
PiperJaffray Reinstates PDL BioPharma, Inc. (PDLI)'s stock to Overweight with the price target of $4. This rating was issued on 12/22/16.
NY Stock News - 3 hours ago
PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It ...
It has been about a month since the last earnings report for PDL BioPharma, Inc. PDLI. Shares have added about 5.9% in that time frame, ...
The Standard - 3 hours ago
Unusual Volume Spikes For: PDL BioPharma, Inc. (NASDAQ:PDLI)
PiperJaffray Reinstates PDL BioPharma, Inc. (NASDAQ:PDLI)'s stock to Overweight with the price target of $4. This rating was issued on ...
HugoPress - 8 hours ago
Stock in Review: PDL BioPharma, Inc. (NASDAQ:PDLI)
After a recent check, PDL BioPharma, Inc.'s ROIC is 0.433886. The ROIC 5 year average is 1.428315 and the ROIC Quality ratio is at 1.299667. ROIC is a widely ...
Yahoo Finance - 3 Apr 2017
Novavax, Inc.'s (NVAX) is at $0.83 per share and PDL BioPharma ...
In current trading day PDL BioPharma, Inc. (PDLI) stock confirmed the flow of 3.59% with the final price of $2.31. Its Average True Range (ATR) ...
HugoPress - 1 day ago
PDL BioPharma, Inc. (NASDAQ:PDLI) Quarterly EPS Analysis
PDL BioPharma, Inc. (PDLI) reported sales (ttm) of 244.3 Million, whereas, 2 number of analysts estimated the mean sale of 50.48 million.
Davidson Register - 1 day ago
Traders Secrets on PDL BioPharma, Inc. (PDLI), Tractor Supply ...
PDL BioPharma, Inc. (NASDAQ:PDLI) plunged -1.44% with the closing price of $2.06. The overall volume in the last trading session was 2.18 ...


Back